You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

REVIEW article

Front. Immunol.

Sec. Inflammation

The significance of component resolved diagnostics in atopic dermatitis

  • 1. Department of Dermatology and Venerology, Medical University of Bialystok, Bialystok, Poland

  • 2. Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland

  • 3. Department of Allergology and Pulmonology, National Research Institute of Tuberculosis and Lung Diseases, Rabka-Zdroj, Poland

  • 4. Faculty of Medicine, Rzeszow University,, Rzeszow, Poland

Article metrics

View details

5

Views

The final, formatted version of the article will be published soon.

Abstract

Atopic dermatitis (AD) is a common and chronic inflammatory skin disease characterized by an abnormal skin barrier, resulting in skin dryness, pruritus, and an increased risk of allergies and secondary infections. AD patients often show hypersensitivity to both food and airborne allergens. Component resolved diagnostics (CRD) offers sIgE testing of individual allergen molecules and provides additional insights, especially in polysensitized patients, in case of sensitization to allergens with low abundance, low stability, or associated with risks of anaphylaxis. It enables the detection of genuine and cross-sensitization or the composition of an allergen immunotherapy vaccine. So far, the utility of CRD in AD has never been thoroughly analyzed. This review provides the basic information about CRD and comprehensively summarizes its potential application in the personalized management of patients with AD. Molecular profiling of allergen components moves closer to explaining the mechanisms of development of different molecular endotypes and clinical phenotypes of AD, provides biomarkers of disease severity, autoimmune IgE responses, and therapeutic response, improving understanding of atopic dermatitis endotypes and treatment outcomes.

Summary

Keywords

allergen components, atopic dermatitis, Atopic march, Component resolved diagnostics, CRD, Molecular allergy diagnostics, precision medicine

Received

23 September 2025

Accepted

16 February 2026

Copyright

© 2026 Błażowska, Nowowiejska, Tomasiak-Łozowska, Błażowski and Flisiak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Małgorzata Błażowska

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics